PPAR alpha

10/15/2008 - "Collectively, our data suggest that SQA and SHQA are novel PPARalpha/gamma dual agonists and may be beneficial for reducing insulin resistance through regulation of adipogenesis."
05/01/2008 - "A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet."
01/01/2007 - "The aim of this study was to evaluate the potential role of PPARalpha in insulin resistance in aging mice induced by a high-fat diet. "
04/01/2004 - "The aim of this study was to clarify the role of PPAR-alpha in the development of insulin resistance using PPAR-alpha knockout (KO) mice and wild-type controls (WT). "
06/01/2003 - "In the present study, we have assessed the transcriptional and physiological responses to PPAR-alpha activation in a diet-induced rat model of insulin resistance. "

05/01/2006 - "The aim of the present study was to evaluate the role of the PPAR-alpha receptor on the development of acute inflammation. "
11/01/2005 - "Cultured cell studies showed that DHEAS may mediate its action by counteracting aging-associated inflammation via PPAR-alpha activation. "
09/01/2014 - "Effect of cold stress on expression of AMPKalpha-PPARalpha pathway and inflammation genes."
01/01/2011 - "PPAR-alpha controls keratinocyte proliferation/differentiation, contributes to wound healing and regulates skin inflammation. "
01/01/2011 - "PPAR-alpha in cutaneous inflammation."

04/01/2006 - "PPAR-alpha suppresses both COX-2 and development of steatohepatitis, while pharmacological inhibition of COX-2 activity ameliorates the severity of experimental steatohepatitis. "
02/01/2005 - "To study the effect of endotoxin on the expression of peroxisome proliferator-activated receptor alpha (PPARa) in the development of nonalcoholic steatohepatitis in rats. "
04/01/2011 - "PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver."
02/01/2008 - "Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation."
09/01/2007 - "The ability of Tox and other hydrocarbon pollutants to induce fatty liver despite being PPARalpha agonists indicates a novel consequence of exposure to this class of chemicals, and may provide a new understanding of fatty liver in populations with industrial exposure."

08/01/2007 - "This review will discuss some of the evidence, both experimental and clinical, that suggests that activation of PPAR alpha and/or gamma in hypertension may exert beneficial cardiovascular protective effects."
04/01/2010 - "(2) The subjects, with a family history of hypertension (OR = 1.44, 95%CI: 1.02 - 2.03) or type 2 diabetes (OR = 3.25, 95CI: 1.28 - 8.20), were significantly increased the occurrence of MS. (3) The genotype (AA, AC, CC) of PPARalpha intron 1A/C was not found to be related to MS. The OR of AC and CC genotype (compared to the genotype AA) were 0.98 (95%CI: 0.70 - 1.36) and 0.75 (95%CI: 0.44 - 1.29), respectively. "
01/01/2008 - "Thus, despite defective fatty acid oxidation, PPARalpha null mice are not hypertensive but develop salt-sensitive hypertension."
08/01/2005 - "Therefore, chronic PPAR-alpha agonist treatment reduces salt-dependent hypertension produced by ETB receptor blockade in male and female Sprague-Dawley rats. "
02/26/2002 - "We demonstrate that variation in the PPARalpha gene influences human left ventricular growth in response to exercise and hypertension, indicating that maladaptive cardiac substrate utilization can play a causative role in the pathogenesis of LVH."

09/01/2002 - "Experiments using animal models of atherosclerosis and clinical studies in humans strongly support an anti-atherosclerotic role for PPAR alpha and gamma in vivo. "
08/15/2015 - "In conclusion, AR ameliorated atherosclerosis via the regulation of hepatic lipid metabolism, and AR also contributed to the activation of PPAR-alpha, APOA1, APOA2 and APOC3. "
06/01/2009 - "PPAR alpha activation inhibits vascular smooth muscle proinflammatory responses, attenuating the development of atherosclerosis. "
03/01/2009 - "Since lipid metabolic system defected genetically in AL mice, we suggest that the changes of PPAR alpha, LXR alpha, and their target genes aggravated lipid metabolic disorder in the liver and further accelerated the development of atherosclerosis on a stress of HF diet feeding in AL mice."
03/01/2009 - "The results showed that in AL mice fed with HF diet, plasma lipid levels, hepatic lipid accumulation, and atherogenesis together with upregulated PPAR alpha, LXR alpha, and their target genes, i.e., FAT, SCD1, FAS, Angptl3, and apoB100 significantly increased in a 12-week long feeding period. "